Genmab A (GMAB) Revenue (2018 - 2026)

Genmab A (GMAB) has reported Revenue for 9 consecutive years, with $1.2 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue fell 29.57% year-over-year to $1.2 billion; the trailing twelve-month figure through Jun 2026 stood at $6.4 billion (up 7.04% YoY), and the FY2025 full-year result was $3.7 billion, up 19.19% from the prior year.
• Revenue climbed to $1.2 billion in Q2 2026 per GMAB's latest filing, from $896.0 million in the prior quarter.
• Across five years, Revenue topped out at $4.7 billion in Q3 2023 and bottomed at -$9.4 billion in Q4 2023.
• Historically, Revenue has averaged $628.3 million across 5 years, with a median of $1.2 billion in 2026.
• The sharpest annual moves came in 2022 and 2024: Revenue soared 37.66% in 2022, then slumped 53.67% in 2024.
• Over 5 years, Revenue stood at $322.3 million in 2022, then sank by 3017.97% to -$9.4 billion in 2023, then surged by 123.37% to $2.2 billion in 2024, then grew by 21.11% to $2.7 billion in 2025, then tumbled by 56.61% to $1.2 billion in 2026.
• According to Business Quant data, Revenue over the past three periods registered $1.2 billion, $896.0 million, and $2.7 billion for Q2 2026, Q1 2026, and Q3 2025 respectively.